Publications by authors named "Jordan D Campbell"

Claim this Profile
E
Evaluation of the androgen receptor in patients with ERα-positive early breast cancer treated with adjuvant tamoxifen ± fluoxymesterone.
James N Ingle, Vera J Suman, Malvika H Solanki, Marie R Passow, Jordan D Campbell

Breast Cancer Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses.
Nathan D Seligson, James L Chen, Austin C Goodrich, Brian A Van Tine, Jordan D Campbell

J Immunother Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
Mattia Rediti, Aranzazu Fernandez-Martinez, David Venet, Françoise Rothé, Katherine A Hoadley, Jordan D Campbell

Nat Commun· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age, Body Mass Index, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer Survival.
Marla Lipsyc-Sharf, Karla V Ballman, Jordan D Campbell, Hyman B Muss, Edith A Perez

JAMA Netw Open· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
Aranzazu Fernandez-Martinez, Tomás Pascual, Baljit Singh, Paolo Nuciforo, Naim U Rashid, Jordan D Campbell

JAMA Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).
Alan L Ho, Nathan R Foster, Alex J Zoroufy, Jordan D Campbell, Francis Worden

J Clin Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
Jonathan H Shepherd, Karla Ballman, Mei-Yin C Polley, Jordan D Campbell, Cheng Fan

J Clin Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis